Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As the fulcrum on which the balance between the opposing forces of tolerance and immunity has been shown to pivot, dendritic cells (DC) hold significant promise for immune intervention in a variety of disease states. Here we discuss how the directed differentiation of human pluripotent stem cells may address many of the current obstacles to the use of monocyte-derived DC in immunotherapy, providing a novel source of previously inaccessible DC subsets and opportunities for their scale-up, quality control and genetic modification. Indeed, given that it is the immunological legacy DC leave behind that is of therapeutic value, rather than their persistence per se, we propose that immunotherapy should serve as an early target for the clinical application of pluripotent stem cells.

Original publication

DOI

10.2217/rme.15.6

Type

Journal article

Journal

Regen Med

Publication Date

2015

Volume

10

Pages

275 - 286

Keywords

cancer vaccination, dendritic cells, embryonic stem cells, genome editing, induced pluripotent stem cells, tolerance induction, Dendritic Cells, Humans, Immune Tolerance, Immunotherapy, Monocytes, Pluripotent Stem Cells